Alvotech Swiss AG develops and manufactures biosimilars, with a pipeline focused on monoclonal antibodies and other biologic medicines. The company follows a vertically integrated approach from R&D through drug product manufacturing and collaborates with commercial partners for market access.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development and manufacturing of biosimilars to expand access to affordable biological medicines; integrated activities from R&D to fill-and-finish, with development and clinical services.
Development of biosimilars
Development of a strategic pipeline of monoclonal antibodies and biosimilar candidates for various therapeutic areas, supported by development and clinical services in Europe and Iceland.
Manufacturing of biosimilars
Manufacturing of biosimilars at a facility in Reykjavik using single-use technology, fill-and-finish manufacturing, and capacity expansion according to FDA and EMA cGMP standards.
Partnerships and licensing agreements
Partnerships and licensing agreements for biosimilar assets worldwide, enabling market access and commercial collaboration with partners.
Knowledge
No knowledge articles yet
Once Alvotech Swiss AG has claimed this profile, we'll publish editorial articles and case studies here together.